印度的AI创业企业正在释放无结构的医疗数据,以便在全球制药巨头的支持下推进医疗保健,并驱动印度的55,000B美元的制药增长。 Indian AI startups are unlocking unstructured medical data to advance healthcare, backed by global pharma giants and driving India’s $55B pharmaceutical growth.

AI公司日益注重无结构的临床数据——如医生笔记、实验室报告和医疗图象——占目前传统系统无法获得的保健信息的80%左右。 AI firms are increasingly focusing on unstructured clinical data—like doctor notes, lab reports, and medical images—representing about 80% of health information currently inaccessible to traditional systems. 先进的人工智能工具,如自然语言处理和图像识别等,正在释放出改进诊断、个性化治疗和加速研究的洞见。 Advanced AI tools such as natural language processing and image recognition are unlocking insights that improve diagnostics, personalize treatment, and accelerate research. 包括Eka Care、HealthPlix和Axone Health等印度的创业者正在领导这一转变,得到Eli Lilly、Bristol Myers Squibb和Novo Nordisk等全球制药巨头的支持,这些巨头正在该国扩大AI驱动的创新中心。 Startups in India, including Eka Care, HealthPlix, and Axone Health, are leading this shift, supported by global pharmaceutical giants like Eli Lilly, Bristol Myers Squibb, and Novo Nordisk expanding AI-driven innovation hubs in the country. 印度的制药市场在2025年达到550亿美元,预计到2030年将增长到1200-1300亿美元,这有助于实现印度到2047年实现30-35万亿美元经济这一更广泛的经济目标。 India’s pharmaceutical market reached $55 billion in 2025 and is projected to grow to $120–130 billion by 2030, contributing to the nation’s broader economic goal of a $30–35 trillion economy by 2047.